Key Takeaways
- NuScale Power (SMR) climbed 14.7% during Wednesday’s session to approximately $11.76, followed by an additional 5% uptick after hours.
- A UK government initiative to support small modular reactor development sparked the surge across nuclear stocks.
- RBC’s Chris Dendrinos maintains a Sector Perform rating with a $14 target, cautioning investors about current valuation levels.
- Ongoing class-action lawsuits related to ENTRA1 disclosures pose legal uncertainty, with a critical April 20 deadline approaching.
- Corporate insiders have dumped more than 14 million shares totaling approximately $171M over three months, including a major director sale of 13.5 million shares.
Shares of NuScale Power rocketed 14.7% higher on Wednesday, peaking near $12.02 before closing the regular session around $11.76. Extended trading brought another 5% advance. Trading volume swelled to approximately 57.5 million shares—a massive 119% spike above typical levels.
NuScale Power Corporation, SMR
The trigger behind the surge was a freshly announced UK government funding initiative aimed at accelerating small modular reactor commercialization. While NuScale isn’t receiving direct capital from this package, the announcement lifted optimism throughout the nuclear energy sector. Market participants interpreted the move as validation that policymakers are increasingly committed to supporting advanced nuclear technologies.
Broader equity market conditions also provided tailwinds. With risk appetite recovering, investors have begun revisiting growth-oriented, long-duration stories like NuScale. The company operates at the intersection of three compelling themes: energy independence, carbon reduction goals, and surging electricity demands from AI data centers—a narrative that’s captured increasing investor attention.
Additional momentum came from a Rolls-Royce SMR contract disclosure, which elevated sentiment for US-listed small modular reactor stocks broadly. NuScale enjoyed both the positive sector rotation and what appears to be some short-squeeze dynamics.
Analyst Perspective: Proceed With Caution
Despite the enthusiastic price action, RBC’s Chris Dendrinos remains circumspect. While he recognizes that NuScale is “making incremental forward progress,” he emphasizes that reaching a Final Investment Decision (FID) involves a “protracted timeline.” His Sector Perform stance remains unchanged, and he’s recently adjusted his valuation assumptions upward for discount rates to account for heightened execution uncertainty.
Dendrinos highlights that NuScale’s trajectory hinges substantially on variables beyond management’s direct influence—particularly regulatory greenlight processes and securing third-party capital commitments. Prolonged development schedules heighten dilution probability and complicate precise valuation frameworks. His $14 price objective suggests roughly 20% appreciation potential from present levels, though he’s explicitly advising against momentum-chasing behavior.
Wall Street sentiment overall shows division. Current analyst coverage breaks down to 5 Buy ratings, 6 Hold recommendations, and 1 Sell rating—collectively a Moderate Buy consensus—with a mean price objective of $17.39, suggesting approximately 48.5% upside if operational milestones materialize.
Among the optimistic camp, Bank of America elevated the stock to Neutral with a $28 target during January. Texas Capital issued a Strong Buy recommendation around the same timeframe. Conversely, UBS reduced its forecast to $13, Canaccord dramatically lowered expectations from $60 down to $25, and Citigroup holds a Sell rating with an $11.50 objective. The consensus target averages $20.96.
Material Headwinds Persist
Underlying business metrics remain challenged. NuScale reported earnings per share of -$0.80 in its most recent quarter, significantly undershooting the -$0.10 analyst consensus. Revenue registered just $1.81 million versus $8.76 million expectations. Net margin stands at a deeply negative -1,130%.
Insider transaction activity has raised eyebrows. The chief executive divested 82,667 shares in early March. A board member unloaded a substantial 13.5 million share position valued around $163 million in April. Cumulative insider selling over the past 90 days totals 14.1 million shares worth approximately $171 million. Current insider ownership has contracted to merely 1.2% of outstanding shares.
Legal challenges also cloud the outlook. Multiple law firms are actively pursuing class-action claims centered on alleged ENTRA1 disclosure deficiencies, with April 20 marking the lead-plaintiff motion deadline. These complaints assert material misrepresentations connected to an earlier stock decline of roughly 12%.
Technical indicators show the 50-day moving average positioned at $12.41, while the 200-day moving average sits at $21.21.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
